All In Biotech

Free tool

FAERS Monitor: Iluvien

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201923 or its brand name (Iluvien, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.

Reports

2,447

Serious

1,130

46% of reports

Hospitalization

325

Death reported

51

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective197
  • intraocular pressure increased192
  • off label use169
  • pruritus166
  • rash144
  • diarrhoea115
  • device failure111
  • psoriasis95
  • device dislocation92
  • headache90
  • fatigue89
  • circumstance or information capable of leading to medication error87
  • pain85
  • nausea82
  • condition aggravated81

Reports by year received

View as table
YearReports
20048
200514
20067
200711
20089
200915
201017
201128
201232
201317
201426
201554
201684
201795
2018103
2019267
2020159
2021193
2022248
2023225
2024277
2025356
2026202

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intraocular pressure increasedSignal192131.1114.324,300
device failureSignal11163.152.66,679
circumstance or information capable of leading to medication errorSignal8722.218.11,738
device dislocationSignal9218.214.91,480
psoriasisSignal956.35.1417
pruritusSignal1663.73.2332
rashSignal1442.82.4173
condition aggravatedSignal812.31.858
off label use1691.71.445
diarrhoea1151.51.321
drug ineffective1971.31.113
headache901.21.04
pain851.21.02
fatigue891.00.80
nausea820.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.